These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 3018469)

  • 1. Human T-lymphotropic virus type III/lymphadenopathy-associated virus: agent summary statement.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Aug; 35(34):540-2, 547-9. PubMed ID: 3018469
    [No Abstract]   [Full Text] [Related]  

  • 2. Leads from the MMWR. Human T-lymphotropic virus type III/lymphadenopathy-associated virus: agent summary statement.
    JAMA; 1986 Oct; 256(14):1857, 1861, 1868 passim. PubMed ID: 3020262
    [No Abstract]   [Full Text] [Related]  

  • 3. Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. Centers for Disease Control, Department of Health and Human Services.
    Ann Intern Med; 1986 Oct; 105(4):558-9. PubMed ID: 3019202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human T-lymphotropic virus type III/lymphadenopathy-associated virus antibody testing at alternate sites.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 May; 35(17):284-7. PubMed ID: 3010070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update: evaluation of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection in health-care personnel--United States.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1985 Sep; 34(38):575-8. PubMed ID: 2993842
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Jun; 35(23):376-8, 383. PubMed ID: 3012309
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV/lymphadenopathy-associated virus: agent summary statement. Centers for Disease Control.
    Ohio Med; 1988 Feb; 84(2):127-31. PubMed ID: 2830566
    [No Abstract]   [Full Text] [Related]  

  • 8. Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus in the workplace.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1985 Nov; 34(45):681-6, 691-5. PubMed ID: 2997587
    [No Abstract]   [Full Text] [Related]  

  • 9. Agent summary statement for human immunodeficiency viruses (HIVs) including HTLV-III, LAV, HIV-1, and HIV-2.
    Centers for Disease Control (CDC)
    MMWR Suppl; 1988 Apr; 37(4):1-17. PubMed ID: 2832719
    [No Abstract]   [Full Text] [Related]  

  • 10. [Guidelines for the management of patients infected by the human immunodeficiency virus].
    Ponce de León S; Ruiz-Palacios GM
    Rev Invest Clin; 1988; 40(1):47-63. PubMed ID: 3165542
    [No Abstract]   [Full Text] [Related]  

  • 11. Infection control measures for human immunodeficiency virus (HIV): universal precautions.
    Rettig PJ
    J Okla State Med Assoc; 1988 Sep; 81(9):575-6. PubMed ID: 2846803
    [No Abstract]   [Full Text] [Related]  

  • 12. Human T-lymphotropic virus type III/lymphadenopathy-associated virus antibody prevalence in U.S. military recruit applicants.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Jul; 35(26):421-4. PubMed ID: 3014305
    [No Abstract]   [Full Text] [Related]  

  • 13. Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States. Centers for Disease Control, Department of Health and Human Services.
    Ann Intern Med; 1985 Sep; 103(3):402-3. PubMed ID: 2992336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus during invasive procedures.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Apr; 35(14):221-3. PubMed ID: 3007970
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety issues raised by worker's infection with AIDS virus.
    Palca J
    Nature; 1987 Sep 17-23; 329(6136):191. PubMed ID: 3627260
    [No Abstract]   [Full Text] [Related]  

  • 16. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. Centers for Disease Control, U.S. Department of Health and Human Services.
    Ann Intern Med; 1986 Aug; 105(2):234-7. PubMed ID: 3014942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevalence of antibodies against the lymphadenopathy-associated virus/human T-cell lymphotropic virus type III (LAV/HTLV) in a population of homosexuals in Mexico].
    Sierra Madero JG; Ponce de León S; Ruiz Palacios G; Tinoco JC; Calva JJ; Zamora EE
    Salud Publica Mex; 1986; 28(2):180-5. PubMed ID: 3014666
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV testing for NIH laboratory workers gets under way.
    Palca J
    Nature; 1988 Mar; 332(6163):386. PubMed ID: 3162553
    [No Abstract]   [Full Text] [Related]  

  • 19. Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus during invasive procedures. Centers for Disease Control, Department of Health and Human Services.
    Ann Intern Med; 1986 Jun; 104(6):824-5. PubMed ID: 3010783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of children infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. Recommendations of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services.
    Ann Intern Med; 1987 Jan; 106(1):75-8. PubMed ID: 3024547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.